TREAC

Treace Presents Updated ALIGN3D™ Interim Data and Latest Product Innovations at the 2023 ACFAS Annual Conference

Retrieved on: 
Thursday, February 9, 2023

PONTE VEDRA, Fla., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure today announced it will highlight new interim clinical data from the ALIGN3D™ study, and recent product innovations, at the 2023 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference in Los Angeles, California.

Key Points: 
  • PONTE VEDRA, Fla., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure today announced it will highlight new interim clinical data from the ALIGN3D™ study, and recent product innovations, at the 2023 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference in Los Angeles, California.
  • The scientific poster titled, “Three Year Interim Analysis of a Five-Year Multicenter Study Assessing Radiographic and Patient Outcomes Following Triplanar Tarsometatarsal Arthrodesis with Early Weightbearing”,1 includes an interim analysis of 128 patients from the ALIGN3D™ study with at least 24 months of follow-up following the Lapiplasty® Procedure demonstrating:
    Early return to weight bearing in a walking boot at an average 8.1 days;
    92% and 90% improvement in walking/standing and social interaction patient-reported quality of life measures, respectively, using the Manchester-Oxford Foot Questionnaire (MOxFQ) through 36 months (n=41); and
    John T. Treace, CEO, Founder and Board Member of Treace, said, “We are excited by the updated interim results from our ALIGN3D™ study showing high patient satisfaction with rapid return to weightbearing, low recurrence rates, and significant reduction in pain and patient reported outcome scores at 24 months following the Lapiplasty® procedure.
  • As a company focused on improving surgical outcomes for bunion patients, we are committed to reporting the long-term results of our novel Lapiplasty® procedure though this unique 5-year, multicenter study.”
    During the ACFAS Conference, Treace will feature its current and next-generation technologies at its exhibit booth including the Micro-Lapiplasty™ and SpeedPlate™ systems, which are expected to commercialize later this year.
  • The Company will also be hosting Lapiplasty® and Adductoplasty® surgeon hands-on training labs featuring recently commercialized innovations, including the Lapiplasty® 3-n-1™ Guide, Lapiplasty® S4A Anatomic Plating Kit, and the SpeedRelease™ and TriTome™ tissue release instruments.

Treace Medical Concepts, Inc. Announces Pricing of $100.0 Million Public Offering of Common Stock

Retrieved on: 
Wednesday, February 8, 2023

All of the shares of common stock are being offered by Treace and there are no selling stockholders participating in the offering.

Key Points: 
  • All of the shares of common stock are being offered by Treace and there are no selling stockholders participating in the offering.
  • In addition, Treace has granted the underwriters a 30-day option to purchase up to an additional 714,285 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Treace, are expected to be approximately $100.0 million, excluding any exercise of the underwriters’ option to purchase additional shares.
  • The offering is expected to close February 10, 2023, subject to the satisfaction of customary closing conditions.

Treace Medical Concepts, Inc. Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, February 7, 2023

All of the shares of the common stock are being offered by Treace and there are no selling stockholders in the proposed offering.

Key Points: 
  • All of the shares of the common stock are being offered by Treace and there are no selling stockholders in the proposed offering.
  • In addition, Treace intends to grant the underwriters a 30 day option to purchase up to an additional $15.0 million of shares of its common stock.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
  • J.P. Morgan and Morgan Stanley are acting as lead book-running managers for the proposed offering.

Bragar Eagel & Squire, P.C. Is Investigating BRP, Alico, Treace, and Welltower and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, January 9, 2023

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • BRP is the subject of a report published by NINGI Research on September 13, 2022.
  • On this news, Provident's stock price fell $2.20 per share, or 21.78%, to close at $7.90 per share on November 16, 2022.
  • Based on this report, shares of Welltower have dropped by more than 5% in intraday trading on the same day.

Treace Medical Concepts Provides 2022 Preliminary Unaudited Revenue

Retrieved on: 
Monday, January 9, 2023

PONTE VEDRA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced preliminary unaudited results for fourth quarter and full year 2022.

Key Points: 
  • PONTE VEDRA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced preliminary unaudited results for fourth quarter and full year 2022.
  • Preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be in the range of $49.1 to $49.6 million and $141.2 to $141.7 million, respectively, representing an increase in the range of 47% to 48% and 50% over the same periods last year, respectively.
  • For the full year 2022, Treace previously provided revenue guidance to be in the range of $135 million to $138 million, which represented approximately 43% to 46% growth over the Company’s 2021 revenue.
  • “Preliminary 2022 revenue growth of 50% and fourth quarter revenue growth of 47% to 48% demonstrate the underlying strength and effectiveness of our strategic investments into our direct sales channel, direct-to-consumer programs, and targeted R&D initiatives.

TREACE ALERT: Bragar Eagel & Squire, P.C. is Investigating Treace Medical Concepts, Inc. on Behalf of Treace Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, December 31, 2022

NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NASDAQ: TMCI) on behalf of Treace stockholders.

Key Points: 
  • NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NASDAQ: TMCI) on behalf of Treace stockholders.
  • Our investigation concerns whether Treace has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On November 15, 2022, Culper Research published a short report on Treace (the "Culper Report").
  • On this news, Treace's stock price fell $3.57 per share, or 14.81%, to close at $20.54 per share on November 15, 2022.

Treace Receives FDA 510(k) Clearance for SpeedPlate™ Rapid Compression Implant Technology

Retrieved on: 
Monday, November 28, 2022

The SpeedPlate System was designed for rapid delivery of titanium compression implants, serving as enabling fixation technology with Treaces new Micro-Lapiplasty instrumentation which allows the patented Lapiplasty procedure to be performed through small, 2cm incisions.

Key Points: 
  • The SpeedPlate System was designed for rapid delivery of titanium compression implants, serving as enabling fixation technology with Treaces new Micro-Lapiplasty instrumentation which allows the patented Lapiplasty procedure to be performed through small, 2cm incisions.
  • The SpeedPlate implant platform also serves as a versatile addition to the Companys fixation portfolio, with broad compatibility with conventional Lapiplasty, Lapiplasty Mini-Incision, and Adductoplasty procedures/systems.
  • We are pleased to announce 510(k) clearance of our SpeedPlate technology.
  • Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities.

Treace Announces First Patient Treated in MTA3D™ Adductoplasty® Clinical Study

Retrieved on: 
Monday, November 21, 2022

With the first patient now treated, we look forward to advancing the MTA3D Clinical Study and reporting on outcomes following the procedures.

Key Points: 
  • With the first patient now treated, we look forward to advancing the MTA3D Clinical Study and reporting on outcomes following the procedures.
  • Our MTA3D Clinical Study reinforces our focused leadership in the surgical correction of bunions, as well as our commitment to building upon our differentiated clinical body of evidence.
  • The MTA3D Clinical Study is a prospective, multicenter, post-market study designed to evaluate outcomes of the combined Adductoplasty and Lapiplasty Procedures for patients in need of metatarsus adductus and hallux valgus corrective surgery.
  • The study will evaluate for consistent, maintained radiographic correction and patient reported outcome scores following combined Adductoplasty and Lapiplasty procedures.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Treace Medical Concepts, Inc. and Encourages Investors with Losses to Contact the Firm

Retrieved on: 
Tuesday, November 22, 2022

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (Treace or the Company) (NASDAQ: TMCI ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (Treace or the Company) (NASDAQ: TMCI ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • Treace is the subject of a report issued by Culper Research on November 15, 2022.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Treace Medical Concepts, Inc. and Encourages Investors with Losses to Contact the Firm

Retrieved on: 
Monday, November 21, 2022

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (Treace or the Company) (NASDAQ: TMCI ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (Treace or the Company) (NASDAQ: TMCI ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • Treace is the subject of a report issued by Culper Research on November 15, 2022.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.